Despite more aggressive disease of the RET-fusion positive cohort, the 2.4% ‘true recurrence’, 2.7% cancer-specific mortality, 96% and 95% survival at 5 and 10 years were comparable to data (approximately 1% ‘true recurrence’, 2–2.5% mortality, 99% and 95% survival at 5 and 10 years) for PTC cohorts with unknown genetic background (Sciuto et al. 2009, Ito et al. 2018). Here, RET is linked to cancer.